Home › Companies › BLTE

Belite Bio

BLTE Rare disease Lead: Phase 3 1 Biotech Distilled article ↓

Metabolic Ophthalmology Small Molecule

Most recent annual filing: 2026-03-31

Pipeline (6 active programs)

tinlarebant

LBS-008

Small Molecule Target: RBP4

Stargardt Disease Type 1 Phase 3 oral
Geographic Atrophy Phase 3 oral

LBS-009

Small Molecule Target: RBP4

Non-Alcoholic Fatty Liver Disease Preclinical oral
Nonalcoholic Steatohepatitis Preclinical oral
Type 2 Diabetes Preclinical oral
Gout Preclinical oral

Biotech Distilled coverage (1)

2026-07-22 Belite Bio (BLTE) — Scientific Deep Dive for Tinlarebant (LBS-008) and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.